Related Experiment Video
Updated: Apr 23, 2026

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
Published on: June 13, 2021
Aripiprazole augmentation of antidepressants for postpartum depression: a preliminary report
Verinder Sharma1, Christina Sommerdyk, Bin Xie
1Western University, London, Ontario, Canada, vsharma@uwo.ca.
Abstract:
We describe the results of an open-label study designed to assess the effectiveness and tolerability of aripiprazole addition to an antidepressant in patients with major depressive disorder with postpartum onset who had not experienced significant clinical improvement following an adequate trial of an antidepressant. Eight of ten women completed the trial with augmentation of aripiprazole (2-10 mg) to their existing antidepressant treatment. Our results suggest a possible therapeutic role for aripiprazole when added to an antidepressant in non-breastfeeding women with postpartum depression. Aripiprazole addition appeared effective and safe with no serious adverse events reported.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Mania and Antimanic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Psychosis and Antipsychotic Drugs: Overview

